Cytokine profile and cardiovascular status in patients with chronic kidney disease after covid-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. description of the cytokine model of the development of the cardiovascular changes in patients with chronic kidney disease (ckd) after new coronavirus infection. material and methods. clinical follow-up and examination of 150 patients with ckd after covid-19 was carried out. the examination included the determination of the interleukin-1 (IL-d, il-6, il-8, tumor necrosis factor a (TNF-a), transforming growth factor p (Tgfpd, hscrp, d-dimer, fibrinogen, ferritin, natriuretic peptide, cystatin c levels, echocardiography, 24-hour blood pressure monitoring, calculation of the glomerular filtration rate according to the ckd-epi formula. results. an increase in the pro-inflammatory cytokine levels, an increase in the hscrp, d-dimer, fibrinogen, ferritin, natriuretic peptide levels, a change in the structural and functional state of the cardiovascular system (CVS) in patients, especially in the first 3 months after a coronavirus infection, were found. Significant deterioration of the functional state of the kidneys during 3 months of follow-up was not observed in the majority of patients. Conclusion. Patients with ckd after new coronavirus infection require the supervision of a nephrologist and a cardiologist to monitor the functional state of the cardiovascular system and kidneys, as well as for the cardio- and nephroprotective therapy prescription.

Full Text

Restricted Access

About the authors

Denis V. Zhmurov

Tyumen State Medical University

Email: zhmdenis@yandex.ru
Cand.Sci. (Med.), Associate Professor at the Department of Propaedeutic and Faculty Therapy 54 Odesskaya st., Tymen, 625023

Vladimir A. Zhmurov

Tyumen State Medical University

Email: zhmurovva@yandex.ru
Dr. Sci. (Med.), Professor, Head of the Department of Propaedeutic and Faculty Therapy Tyumen, Russia

Ivan M. Petrov

Tyumen State Medical University

Dr. Sci. (Med.), Associate Professor, Head of the Department of Medical Informatics and Biological Physics with the UNESCO Bioethics Network Section Tyumen, Russia

Tatyana I. Petelina

Tyumen Cardiology Research Center - Branch of the Tomsk National Medical Research Center

Dr. Sci. (Med.), Leading Researcher, Department of Arterial Hypertension and Coronary artery insufficiency, Scientific Department of Clinical Cardiology Tyumen, Russia

Lyudmila I. Gapon

Tyumen Cardiology Research Center - Branch of the Tomsk National Medical Research Center

Dr. Sci. (Med.), Professor, Head of the Scientific Department of Clinical Cardiology, Scientific Director of the Department of Arterial Hypertension Tyumen, Russia

Elena I. Yaroslavskaya

Tyumen Cardiology Research Center - Branch of the Tomsk National Medical Research Center

Dr. Sci. (Med.), Head of the Laboratory of Instrumental Diagnostics Tyumen, Russia

Yulianna A. Petrova

Tyumen State Medical University

Cand. Sci. (Med.), Associate Professor at the Department of Propaedeutic and Faculty Therapy Tyumen, Russia

Ekaterina A. Zhmurova

Tyumen State Medical University

Medical Resident at the Department of Internal Medicine, Outpatient Therapy and Family Medicine Tyumen, Russia

Anna A. Ermakova

Tyumen State Medical University

Email: ermackovaanka@yandex.ru
Tyumen, Russia

Polina A. Ermakova

Tyumen State Medical University

Email: poli263@mail.ru
Faculty of Medicine, Department of Propaedeutic and Faculty Therapy Tyumen, Russia

References

  1. Мухин Н.А. Нефрология. Национальное руководство. Краткое издание. М., 2016. 606 с.
  2. Yuan J., Zou X.R., Han S.P., et al. Prevalence and riskfactorsfor cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE).BMC. Nephrol. 2017;18-23.
  3. Муркамилов И.Т., Фомин В.В., Айтбаев К.А. и др. Цитокиновая модель развития сердечно-сосудистых осложнений при хронической болезни почек. Клин. нефрология. 2017;2:71-5.
  4. Cheung C.M., Wright J.R.,Shurrab A.D. Epidemiology of renal dysfunction and patients outcome in atherosclerotic renal occlusion. J. Am. Soc. Nephr. 2002;13;149-57.
  5. Chan R.W., Lai F.M., Li E.K., et al. Urinary mononuclear cell and disease activity of systemic lupus erythematosus. Lupus. 2006;15:262-67.
  6. Бобкова И.Н., Чеботарева Н.В., Козловская Н.В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста b1 как показатель прогрессирования хронического гло-мерулонефрита. Терапевтический архив. 2006;5:9-14.
  7. Кетлинский С.А., Симбирцев А.С. Цитокины. СПб., 2008. 552 с.
  8. Жмуров В.А., Осколков С.А., Казеко Н.И. Хронический пиелонефрит у жителей различных климато-географических регионов. Тюмень, 2006. 304 с.
  9. Радаева О.А., Симбирцев А.С. Клинико-патогенетические особенности взаимодействия системы интерлейкина 1 и классических вазопрессор-ных факторов у больных эссенциальной артериальной гипертензией. Цитокины и воспаление. 2015;3(14):83-9
  10. Адаменко Г.П., Головко Е.С., Скребло Е.И. Маркеры внутрисосудисто-го воспаления и профиль цитокинов при артериальной гипертензии. Проблемы здоровья и экологии. 2014;4-44
  11. Михайлова Л.В., Шелег Д.О., Богачев Р.С. COVID-19 и поражение почек. Клиническая нефрология. 2021;4(13):61-6
  12. Coca A., Burballa C. Centellas-Perez F.J., et al. Outcomes of COVID-19 Among Hospitalized Patients With Non-dialysis CKD. Front. Med. (Lausanne). 2020;7:615312. doi: 10.3389/fmed.2020.615312.
  13. Ng J.H., Hirsch J.S., Hazzan A., et al. Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury. AJKD. 2021;77(2). Doi link: https://doi.org/10.1053//2020.09.002.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies